Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates ofStreptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the1997-1998 respiratory season
Me. Jones et al., Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates ofStreptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the1997-1998 respiratory season, ANTIM AG CH, 44(2), 2000, pp. 462-466
From 8,419 worldwide clinical isolates of Streptococcus pneumoniae obtained
during 1997-1998, 69 isolates with reduced susceptibility or resistance to
fluoroquinolones (FQs) were molecularly characterized. For the isolates in
this prevalence study, only parC (Ser-79-->Tyr) and gyrA (Ser-81-->Phe or
Tyr) mutations, especially in combination, were found to contribute signifi
cantly to resistance. These mutations influenced the FQ MICs to varying deg
rees, although the rank order of activity remains independent of mutation t
ype, with ciprofloxacin the least active, followed by levofloxacin, gatiflo
xacin/grepafloxacin/moxifloxacin/sparfloxacin/trovafloxacin, and clinafloxa
cin/sitafloxacin. Efflux likely plays a crucial role in reduced susceptibil
ity for new hydrophilic FQs.